Subscribe: Market Wire - Pharmaceuticals and Biotech: Drugs
http://img.marketwire.com/rss/mwPBDR.rss
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
announces  cannabis  company  jun  june  marketwired jun  marketwired june  marketwired  medical  new  pain  pleased announce 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Drugs

Marketwired - Drugs



Marketwired - Drugs



Last Build Date: Wed, 28 Jun 2017 11:18:56 EDT

Copyright: Copyright: (C) Marketwired
 



Freedom Leaf Inc. To Acquire Green Market Europe Of Spain, Over 60,000 Square Feet of Operational Greenhouse, Producing Legal Cannabinoids and Hemp Products from EU Certified Hemp for International Markets

Wed, 28 Jun 2017 10:11:38 EDT

Including over 20,000 square feet with an automated light deprivation system, the facilities are owned free and clear, with no debt




Critical Outcome Technologies Addresses Recent Trading Activity

Wed, 28 Jun 2017 09:15:00 EDT

LONDON, ON and BOSTON, MA--(Marketwired - June 28, 2017) - Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company") announces, in response to the recent trading activity in its stock, that it has no material changes to report at this time. The Company believes the recent trading activity relates to the planned share consolidation announced on June 23, 2017.




Pivot Pharma's PBDs Target DNA Damage and Genomic Instability to Treat Cancer -- SECFilings.com

Wed, 28 Jun 2017 09:00:00 EDT

REDONDO BEACH, CA--(Marketwired - Jun 28, 2017) -  SECFilings.com, a leading financial news and information portal offering free real-time public company filing alerts, announces the publication of an article covering novel Pyrrolobenzodiazepine dimers (PBDs) from Pivot Pharmaceuticals Inc. (OTCQB: PVOTF), representing one of the most promising types of therapeutics in the space.




Tetra Bio-Pharma Expands Focus of Commercialization Activities into the Lucrative Veterinary Market

Wed, 28 Jun 2017 08:00:00 EDT

OTTAWA, ONTARIO--(Marketwired - June 28, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF), announced today that it will also commercialize novel cannabinoid based formulations for the treatment of pet conditions.




DNA Brands Signs Letter Of Intent to Acquire Online Medical Company

Wed, 28 Jun 2017 07:30:00 EDT

FORT LAUDERDALE, FL--(Marketwired - Jun 28, 2017) - DNA Brands, Inc. (OTC PINK: DNAX) is pleased to announce that it has signed a Letter of Intent (LOI) to acquire the majority ownership of an Online Medical Resource Company. Its founder, a Medical Doctor of 25 years, will also be joining the DNA Brands management team.




Brisk Sales Lead to Re-Orders and New Orders - Nutritional High's "FLI" Brand Penetrating the Colorado Market

Wed, 28 Jun 2017 07:30:00 EDT

TORONTO, ONTARIO--(Marketwired - June 28, 2017) - Nutritional High International Inc. (the "Company" or "Nutritional High") (CSE:EAT)(CSE:EAT.CN)(CNSX:EAT)(OTCQB:SPLIF)(FRANKFURT:2NU) is pleased to announce multiple re-orders of FLI-branded vape pen cartridges by Starbuds dispensaries and Natures Herbs dispensaries in Colorado, and an initial order filled for Rocky Mountain Blaze.




Advantis Corp. Taking Delivery of More Efficient Amstercan Canning Machine, May Add Mobile Canning Service

Wed, 28 Jun 2017 05:45:00 EDT

NEWPORT BEACH, CA--(Marketwired - Jun 28, 2017) - ADVANTIS CORPORATION (OTC PINK: ADVT) is scheduled to receive the custom made canning machine that N2Pack manufactured for them by the end of this month. The company is working to allow for the Amstercan packaging solution to set up mobile canning services with their existing canning machine.




Cura-Can Health Corp. Enters Business Services Agreement With MCI Medical Clinics Inc.

Tue, 27 Jun 2017 16:58:27 EDT

TORONTO, ONTARIO--(Marketwired - June 27, 2017) - Cura-Can Health Corp. ("Cura-Can" or the "Company"), a private, federally incorporated company, is pleased to announce that it has entered into a business services agreement with MCI Medical Clinics Inc. ("MCI"), one of the largest primary medical care groups in Canada with 24 clinics across Ontario and Alberta. Under the agreement Cura-Can's wholly-owned subsidiary, The Clinic Network Canada Inc. ("TCNC"), will provide, at mutually agreed MCI locations, education, educational materials, signage and staff (including nurse educators and physicians), to help MCI patients determine if they qualify and to assist them in navigating the medical cannabis process. The agreement has a term of five years and may be renewed with the mutual consent of the parties.




QS/1 Names New President

Tue, 27 Jun 2017 13:30:00 EDT

Saul Factor, RPh to head pharmacy software solutions leader




National Brain Tumor Society Announces Multitude of New Discoveries to Enable Potential Future Brain Tumor Treatments

Tue, 27 Jun 2017 12:05:41 EDT

National Brain Tumor Society shares updates on the portfolio of progress being made through its subsidiary, Cure GBM, LLC, and its flagship program, the Defeat GBM Research Collaborative




Enrollment to Begin in OncBioMune's Trial of ProscaVax for Prostate Cancer in Mexico

Tue, 27 Jun 2017 10:42:41 EDT

BATON ROUGE, LA--(Marketwired - June 27, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, a proprietary cancer vaccine technology and commercialization of a portfolio of products internationally, today announces that the Company has been advised that the Mexico health authority, Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) is officially authorizing commencement of the study. OncBioMune is working with the host hospital, principal investigators and others involved in the trial to begin enrollment immediately.




Wanderport Corporation Unveils Premium CBD Coffee Blends

Tue, 27 Jun 2017 09:48:44 EDT

SANTA MONICA, CA--(Marketwired - Jun 27, 2017) - Wanderport Corporation (OTC: WDRP) is pleased to announce that amid growing sales on Amazon.com for the Company's premium quality hemp coffee blends, trial sales of the CBD coffee blends have proven successful, creating expectation for the Company's official Cannabidiol (CBD) product line release into the online marketplace.




Avadim Technologies Inc. Showcases Its Topical Muscle Nutrition Therapies at 68th National Athletic Trainers' Association Clinical Symposia & AT Expo

Tue, 27 Jun 2017 09:36:58 EDT

PHUEL Recognized by Athletic Trainers and Leading Clinicians To Train Harder & Recover Faster




VUCA Health Collaborates With Magellan Rx Management to Enhance Member Knowledge and Adherence

Tue, 27 Jun 2017 09:30:00 EDT

LAKE MARY, FL--(Marketwired - Jun 27, 2017) - VUCA Health today announced that Magellan Rx Management, the pharmacy benefit management division of Magellan Health, will be the first company to utilize its new Medication Management video library. VUCA Health, the industry leader in providing video content to inform patients about medications, has created a new library focused on educating consumers on important topics related to ensuring access and achieving optimal results from medications. Some topics covered by this new library include: the importance of medication adherence, the benefits of medication therapy management, the safe use of opioid medications and certain aspects of prescription drug coverage.




The Alliance for Regenerative Medicine Announces the Appointment of Janet Lynch Lambert as Chief Executive Officer

Tue, 27 Jun 2017 09:30:00 EDT

WASHINGTON, DC--(Marketwired - Jun 27, 2017) - The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the gene and cellular therapies and broader regenerative medicine sector, formally announces that its Board of Directors has named Janet Lynch Lambert as the organization's first chief executive officer. The organization informed its membership early last week of the decision.




AXIM Biotechnologies (OTCQB: AXIM) Takes on Opioid Epidemic with New Patent -- SECFilings.com

Tue, 27 Jun 2017 09:30:00 EDT

AXIM is a major investment of Medical Marijuana, Inc. (OTC PINK: MJNA), the first publicly traded cannabis company




CV Sciences, Inc. to Exhibit and Present at the American Association of Naturopathic Physicians 2017 National Conference

Tue, 27 Jun 2017 08:45:00 EDT

Company Aims to Increase National Awareness and Continues to Expand Its Distribution Network to Licensed Naturopathic Physicians




American Cannabis Company, Inc. Announces It Has Secured A Contract With A New Client In Colorado

Tue, 27 Jun 2017 08:30:00 EDT

DENVER, CO--(Marketwired - Jun 27, 2017) - American Cannabis Company, Inc. (OTCQB: AMMJ) ("ACC"), a full-service business-to-business consulting solutions provider, and seller of ancillary products to the cannabis industry, today announced it has secured a local client in the state of Colorado. This client, Bud Fox Enterprises LLC and Ty Webb Enterprises LLC, will have a multi-location business comprised of state-of-the-art greenhouse cultivation and extraction. ACC will provide end-to-end solutions for this new client, which include operational planning activities, conceptual design work, application completion, deployment of operations and ongoing remote management. ACC has worked with its set of preferred vendors and technology to provide this client with a top-notch business infrastructure.




Wanderport Corporation Launches Online Retailing of Premium Hemp Coffee Blends on Amazon

Tue, 27 Jun 2017 08:30:00 EDT

SANTA MONICA, CA--(Marketwired - Jun 27, 2017) - Wanderport Corporation (OTC: WDRP), is pleased to announce the Company has commenced product sales and distribution on Amazon.com, the largest Internet-based retailer in the world by total sales and market capitalization.




Rennova Health Partners With Certainty Health to Deliver Direct to Consumer Molecular Testing for Psychiatric Disorders

Tue, 27 Jun 2017 08:30:00 EDT

WEST PALM BEACH, FL--(Marketwired - June 27, 2017) - Rennova Health, Inc. (NASDAQ: RNVA), (NASDAQ: RNVAZ) ("Rennova" or the "Company"), a vertically integrated provider of industry-leading diagnostics and supportive software solutions for healthcare providers, announced today an agreement between its subsidiary Advanced Molecular Services Group, Inc. (AMS Group) and Certainty Health, LLC, a pioneer in cloud-based mobile applications for patient-focused health information. The partnership will develop next generation smartphone tools to enable patients, families, and their healthcare teams to confidently assess the importance of a patients' genetic background in treatment decisions for various psychiatric diseases.




UPDATE - Cosmos Holdings Signs Letter of Intent To Acquire CC Pharma GmbH A Leading Re-importer of EU Pharmaceuticals to Germany

Tue, 27 Jun 2017 08:00:00 EDT

CC Pharma GmbH had revenues of approximately $200M in 2016




Golden Leaf Announces Signing of Definitive Agreement for Strategic Acquisition in Canada

Tue, 27 Jun 2017 08:00:00 EDT

TORONTO, ON --(Marketwired - June 27, 2017) - Golden Leaf Holdings Ltd. ("GLH" or the "Company") (CSE: GLH) (CSE: GLH.CN) (CNSX: GLH) (OTCQB: GLDFF), a leading cannabis oil solutions company built around recognized brands, is pleased to announce that it has entered into a definitive agreement in connection with its previously announced acquisition (the "Acquisition") of all of the issued and outstanding shares of Medical Marihuana Group Corporation ("MMGC") and Medical Marihuana Group Consulting Ltd. ("MMCC"). MMGC has filed an application with Health Canada for a cultivation license. MMGC does not currently have any substantial operations and it will not be able to engage in the production of marijuana until it receives the cultivation license.




ViaDerma, Inc. Receives National Drug Code (NDC) from the FDA for Prolayed, Its New OTC Drug for Premature Ejaculation for Men

Tue, 27 Jun 2017 08:00:00 EDT

The Company's National Drug Code for its Prolayed uses Lidocaine & the Company's Proprietary Topical Solution to Solve Premature Ejaculation for Men Can Now be Sold in Retail Stores




Pieris Pharmaceuticals Added to the Russell 2000(R) and Russell 3000(R) Indexes

Tue, 27 Jun 2017 08:00:00 EDT

BOSTON, MA--(Marketwired - June 27, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that the Company has been added to the Russell 2000® and the Russell 3000® Indexes at the conclusion of the Russell US Indexes annual reconstitution, which took effect after the US market closed on June 23, 2017.




IntelGenx Receives USPTO Notice of Allowance for Oral Film Dosage Form Technology Patent

Tue, 27 Jun 2017 08:00:00 EDT

SAINT LAURENT, QUEBEC--(Marketwired - June 27, 2017) - IntelGenx Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) ("IntelGenx"), a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilmT technology platform, today announced that the United States Patent and Trademark Office ("USPTO") has granted a notice of allowance for US Patent Application 13/748,241, entitled "Solid oral film dosage forms and methods for making same." This platform patent discloses oral film dosage forms designed for immediate or sustained release of an active to the buccal and/or sublingual mucosa and will protect several of IntelGenx' oral film products.




Biosimilar Development: Lessons Learned from Early Clinical Studies, New Webinar Hosted by Xtalks

Tue, 27 Jun 2017 07:30:00 EDT

TORONTO, ON--(Marketwired - June 27, 2017) - During a live broadcast on Tuesday, July 18, 2017, scientists from Celerion will share key learnings gained from engagement with multiple biosimilar programs for approval in the US and EU.




Moleculin Announces Conference Call to Discuss Recent New Discovery for Pancreatic Cancer and Business Update

Tue, 27 Jun 2017 07:30:00 EDT

Call Scheduled for this Thursday, 6.29.17 at 4:30 PM ET




Global Pharma Companies Begin Conducting Comparative Effectiveness Research During Phase 3 of Product Development

Mon, 26 Jun 2017 21:08:00 EDT

67% of surveyed market access teams conduct CER during Phase 3




Effective Today Freedom Leaf Inc Uplists to (OTCQB: FRLF); Poised For International Expansion Mainstreaming The Marijuana Legalization Company

Mon, 26 Jun 2017 09:45:00 EDT

Trading on the QB will enhance our visibility in the market, broaden & diversify our investor base, and increase the liquidity of our stock




National Opioid Addiction Treatment Leader Launches Center in Dallas

Mon, 26 Jun 2017 09:00:00 EDT

CleanSlate Continues Expansion of Physician-led Effort to Fight the Opioid Epidemic in Texas; Commits to Working with All Insurers so that Treatment is Available to All in Need




Advantis Corp. Connects At Industry Outreach Event

Mon, 26 Jun 2017 08:45:00 EDT

NEWPORT BEACH, CA--(Marketwired - Jun 26, 2017) - ADVANTIS CORPORATION (OTC PINK: ADVT) CEO, Christopher Swartz, attended the Coastal Pacific political action committee's Southern California Outreach Dinner last Tuesday night. The event was a fundraiser to support cannabis legalization. Swartz was an invited guest of Speedweed CEO, AJ Gentile.




Marina Biotech Appoints Chief Commercial Officer to Lead Sales and Marketing of Prestalia(R)

Mon, 26 Jun 2017 08:30:00 EDT

Company to narrow its business focus to pain and hypertension; Company plans to sell or divest the oligonucleotide therapeutic assets




Propanc Biopharma Receives Orphan Drug Designation from FDA for Treatment of Pancreatic Cancer

Mon, 26 Jun 2017 08:30:00 EDT

Pathway Set for PRP to Progress to First-In-Human Studies




Atossa Genetics Receives Positive Safety Committee Assessment of First Cohort Receiving Oral Formulation of Endoxifen in Phase 1 Dose Escalation Study

Mon, 26 Jun 2017 08:00:00 EDT

SEATTLE, WA--(Marketwired - Jun 26, 2017) - Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has received a positive interim safety assessment of the first cohort receiving proprietary oral Endoxifen in its Phase 1 dose escalation study. Endoxifen is an active metabolite of the FDA approved drug tamoxifen, which is indicated for breast cancer and breast cancer prevention in high-risk patients. The Independent Safety Committee reviewed the blinded data generated from the first cohort receiving the oral formulation (8 subjects) and concluded that the study may advance to the next oral dosing level.




Corbus Pharmaceuticals Announces Inclusion in Russell 3000(R) Index

Mon, 26 Jun 2017 08:00:00 EDT

NORWOOD, MA--(Marketwired - June 26, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it was added to the Russell 3000® Index at the conclusion of the Russell indexes annual reconstitution on June 23, 2017.




Easton Pharmaceuticals Announces It Has Received $400,000 USD In Product Purchase Orders For The Current Quarter From Its Woman's Diagnostic And Treatment Products Business For The Mexico Market

Mon, 26 Jun 2017 08:00:00 EDT

TORONTO, ON--(Marketwired - Jun 26, 2017) - Easton Pharmaceuticals, Inc. (OTC: EAPH), is pleased to announce it has received an approximate total of $400,000 USD in purchase orders for the quarter from its sub-distributors for the Mexican market.




Moleculin Announces Scientific Support for Research Endeavor at Mayo Clinic

Mon, 26 Jun 2017 07:30:00 EDT

HOUSTON, TX--(Marketwired - June 26, 2017) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has entered into an agreement with a physician at the Mayo Clinic to enable additional research on Moleculin's WP1066 molecule for the possible treatment of a rare form of pediatric brain tumor.




Vascular and Neural Complications in Rodent Models of Obesity and Type 2 Diabetes, New Webinar Hosted by Xtalks

Mon, 26 Jun 2017 07:30:00 EDT

In a live session on Wednesday, July 12, 2017 featured speaker Dr. Mark Yorek, Professor of Medicine at University of Iowa and Associate Chief of Staff for Research at Iowa City VA, will present vascular and neural complications in rodent models of obesity and type 2 diabetes. Specifically, he will present the characterization of peripheral neuropathy in translational animal models such as the ZDSD rat




Two Ogilvy CommonHealth Worldwide Executives Appointed to Judge the 2017 MM&M Awards

Mon, 26 Jun 2017 07:00:00 EDT

PARSIPPANY, NJ--(Marketwired - Jun 26, 2017) -  Ogilvy CommonHealth Worldwide (www.ogilvychww.com), the health behavior change specialists of Ogilvy & Mather (www.ogilvy.com), and a WPP Health & Wellness company (NASDAQ: WPPGY) (www.wpp.com), today announced two of the network's executives, Scott Watson and Johanna Skilling, from the New Jersey office have been selected as jurors for the 2017 MM&M Awards.




ICC International Cannabis Corporation Announces New CEO to Support Global Growth Strategy

Mon, 26 Jun 2017 06:44:01 EDT

VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 26, 2017) - ICC International Cannabis Corporation ("ICC" or the "Company") (TSX VENTURE:ICC), a fully licensed producer and distributor of medical and recreational cannabis and cannabinoid extracts, today announced the promotion of Mr. Alejandro Antalich to Chief Executive Officer, and the appointment of Mr. Diego Taranto to Senior Financial Controller. These management changes come at a time when the Company is transitioning from an early stage licensed producer to a fully licensed producer and distributor of recreational cannabis in Uruguay. Mr. Guillermo Delmonte has stepped down as CEO effective today and will assist Mr. Antalich in the transition of responsibilities.




San Diego trade mission to Vancouver announces Phoenix Molecular Designs' expansion into the USA

Fri, 23 Jun 2017 16:45:29 EDT

VANCOUVER, BC--(Marketwired - June 23, 2017) - San Diego Mayor Kevin Faulconer is leading a trade mission of 26 delegates to Vancouver on Monday, June 26 to promote shared economic goals involving sustainable technologies and to promote partnership in building infrastructure in the life science sector.




Cosmos Holdings Signs Letter of Intent To Acquire CC Pharma GmbH A Leading Re-importer of EU Pharmaceuticals to Germany

Fri, 23 Jun 2017 15:44:30 EDT

CC Pharma GmbH had revenues of approximately $200M in 2016




Jacobson Pharma Announces 2017 Annual Results

Fri, 23 Jun 2017 12:33:38 EDT

Revenue Increases 15.9% to HK$1,256.0 Million; Adjusted Net Profit Up by 30.7% to HK$201.9 Million; Recommends a Final Dividend of HK1.4 Cents per Share




Cannabis Science Invests in the Research and Development of Cannabinoid-based Medications to Treat COPD and Asthma

Fri, 23 Jun 2017 09:14:44 EDT

IRVINE, CA--(Marketwired - Jun 23, 2017) -  Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that it has invested in the research and development of new cannabinoid-based medications to treat Chronic Obstructive Pulmonary Disease (COPD) and Asthma. According to the Centers for Disease Control and Prevention, in the U.S. alone over 15 million people have been diagnosed with COPD, and over 25 million with Asthma.




Mexico Officially Legalizes Medical Marijuana -- CFN Media

Fri, 23 Jun 2017 09:00:00 EDT

SEATTLE, WA--(Marketwired - Jun 23, 2017) - CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing the business potential and implications of Mexico's recent legalization of medical marijuana. Medical Marijuana Inc. (OTC PINK: MJNA) is already well established there, having gained the Mexican government's first-ever permit to import a cannabis-derived product, RSHO-XT, in February of 2016.




Critical Outcome Technologies Announces Share Consolidation

Fri, 23 Jun 2017 08:30:00 EDT

LONDON, ON and BOSTON, MA--(Marketwired - June 23, 2017) - Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that in accordance with the approval of the Company's shareholders obtained on October 13, 2016, its Board of Directors has resolved to proceed with a consolidation of the Company's issued and outstanding common shares on the basis of ten pre-consolidation common shares for one post-consolidation common share (the "Consolidation"). The Consolidation will provide the Company flexibility with respect to attracting institutional investors that may otherwise be precluded from investing in securities trading below a certain price and support future equity financings.




Cannabis Wheaton Announces Offering Update

Fri, 23 Jun 2017 08:00:00 EDT

VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 23, 2017) -




Integrating Equipment Design, Logistics Processes and Real-Time Informatics: The Arrival of QbD in Pharmaceutical Logistics, New Webinar Hosted by Xtalks

Fri, 23 Jun 2017 07:30:00 EDT

Industry expert Mark W. Sawicki, Ph.D., chief commercial officer at Cryoport to discuss the Quality by Design process as it relates to logistics and evaluate its benefits during a live broadcast on Tuesday, July 11, 2017




Axiom Real-Time Metrics Showcasing Fusion eClinical Suite at the Outsourcing in Clinical Trials: Medical Devices 2017

Thu, 22 Jun 2017 15:46:27 EDT

TORONTO, ON--(Marketwired - June 22, 2017) - Axiom Real-Time Metrics, the premier provider of eClinical solutions and services to small to mid-sized life sciences organizations, is exhibiting at the Outsourcing in Clinical Trials: Medical Devices 2017 in Santa Clara, California, June 27-28, 2017. Axiom encourages attendees to join the team for a conversation over coffee at Booth 06.




Centralized Adaptive Trial Design Teams Facilitate Communication Between Global & Country-Level Pharma Teams

Thu, 22 Jun 2017 15:41:00 EDT

65% of surveyed global life science teams have a centralized adaptive trial reporting structure




ECPO-Subsidiary Immunotech Laboratories Enters Final Step of Full Commercialization by the BDA post Phase 3 Approval of ITV-1 for HIV/AIDS; Also Announces Issuance of Distribution Agreement for the Ukraine

Thu, 22 Jun 2017 13:24:33 EDT

MONROVIA, CA--(Marketwired - Jun 22, 2017) - Eco Petroleum Solutions, Inc. ((OTC PINK: ECPO) or the "Company") announces that IMMB BG a subsidiary of Immunotech Laboratories, Inc., the Company's subsidiary, has issued an exclusive Distribution Agreement (the "Agreement") for the territory of the Ukraine to LLC Project Development and Implementation Centre Omega ("Omega"). The term of the agreement is for an initial ten-year period with an option to renew the agreement for an additional ten years. The Agreement establishes a price of EUR 3,300 (Euros) per one 8-week cycle of injections or 16 vials. The treatment protocol requires two 8-week cycles of injections administered twice a week with a one-week break between cycles. The ITV-1 treatment will be administered with a combination of different variations of Protease Inhibitors used in the treatment of HIV/AIDS.




Devonian Announces Plans for its Dermatology program of Thykamine(TM)

Thu, 22 Jun 2017 09:00:00 EDT

QUÉBEC CITY, QUÉBEC--(Marketwired - June 22, 2017) -




Devonian annonce ses plans pour son programme en dermatologie du Thykamine(MC)

Thu, 22 Jun 2017 09:00:00 EDT

QUÉBEC, QUÉBEC--(Marketwired - 22 juin 2017) -




The Life Sciences Report Examines How a Fast-Growing Pharma Company Prepares to Launch OTC Nasal Spray

Thu, 22 Jun 2017 08:45:00 EDT

SAN FRANCISCO, CA--(Marketwired - June 22, 2017) - A San Diego-based pharmaceutical company that focuses on over-the-counter medications reported strong Q1/17 results and expects to begin marketing a nasal spray by the end of the year.




UPDATE - Cannabis Science Releases the Chronic Pain CBIS Transdermal Patches to Meet the Overwhelming Demand from Self-Medicating Patients Worldwide as it Continues to Expands its California Dispensary Network

Thu, 22 Jun 2017 08:43:43 EDT

IRVINE, CA--(Marketwired - Jun 22, 2017) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that its new product-development plans are well underway with the release of the first batch of the CBIS Transdermal Patch in response to an overwhelming response from hundreds chronic pain self-medicating patients worldwide with various chronic pain conditions including Neuropathy, Fibromyalgia, Diabetic Nerve Pain, Back Strains, and others.




Canabo Opens Second Nova Scotia Clinic and Announces Appointment of Garry Stewart as Chief Financial Officer

Thu, 22 Jun 2017 08:30:00 EDT

VANCOUVER, BC--(Marketwired - June 22, 2017) - Canabo Medical Inc. (TSX VENTURE: CMM) (OTCQB: CAMDF) ("Canabo" or the "Company") is pleased to announce it has opened its second clinic in Nova Scotia for a total of 22 clinics and partner clinics nationwide. The new clinic, located in Wolfville, Nova Scotia is now accepting referrals. As the second clinic for the province of Nova Scotia, this opening represents a broadening of Canabo's national clinic footprint.




VistaGen Announces Peer-Reviewed Publication in the Scandinavian Journal of Pain Highlighting Orally-Available AV-101's Excellent Safety Profile and Potential as a Non-Opioid Treatment for Neuropathic Pain

Thu, 22 Jun 2017 08:30:00 EDT

SOUTH SAN FRANCISCO, CA--(Marketwired - June 22, 2017) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today a peer-reviewed publication in the Scandinavian Journal of Pain of two Phase 1 clinical studies of the effects of AV-101 (4-Cl-KYN), the Company's CNS prodrug candidate, as a potential non-opioid treatment for neuropathic pain. Safety data from both the single and multi-dose Phase 1 studies indicated that oral AV-101 was extremely safe and well tolerated, with no meaningful difference in adverse events (AEs) at any dose between AV-101 and placebo. Recently published statistically-significant positive results in four well-established preclinical models of pain associated with tissue inflammation and nerve injury, together with the excellent clinical safety profile, pharmacokinetic (PK) characteristics and consistent reductions in three pain measures (allodynia, mechanical and heat hyperalgesia) demonstrated by these studies, support future Phase 2 clinical studies of AV-101 as a potential new non-opioid treatment alternative for neuropathic pain.




Cannabis Science Releases the Chronic Pain CBIS Transdermal Patches to Meet the Overwhelming Demand from Self-Medicating Patients Worldwide as it Continues to Expands its California Dispensary Network

Thu, 22 Jun 2017 08:11:45 EDT

IRVINE, CA--(Marketwired - Jun 22, 2017) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that its new product-development plans are well underway with the release of the first batch of the CBIS Transdermal Patch in response to an overwhelming response from hundreds chronic pain self-medicating patients worldwide with various chronic pain conditions including Neuropathy, Fibromyalgia, Diabetic Nerve Pain, Back Strains, and others.




Lexaria Files New Patent Application

Thu, 22 Jun 2017 08:00:00 EDT

VANCOUVER, BC--(Marketwired - June 22, 2017) - Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the "Company" or "Lexaria") announces the filing of a new provisional patent application and stock and option awards.




Increasing Patient Enrollment and Patient Data Exchange: Digital Transformation in the Clinical Trial Process, New Webinar Hosted by Xtalks

Thu, 22 Jun 2017 07:30:00 EDT

Join this informative session as the speakers discuss ways to stimulate greater and faster recruitment as well as improve patient and research data harmonization and exchange, through a digital transformation




The Importance of Dose Prediction for Early Drug Development, New Webinar Hosted by Xtalks

Thu, 22 Jun 2017 07:00:00 EDT

TORONTO, ON--(Marketwired - June 22, 2017) - During a live broadcast on Thursday, July 6, 2017, Dr. Robert Harris, Chief Technical Officer at Juniper Pharma Services and Dr. Graham Trevitt, Director (DMPK Consultancy, Modelling and Simulation) at XenoGesis will provide insight into how their joint consultative approach can help drug developers better understand the absorption and clearance characteristics of a drug substance and how these properties can influence dose prediction and selection of an appropriate formulation strategy.




Nemus Bioscience Announces NB1111 Data Presentation at the 27th Annual Symposium of the International Cannabinoid Research Society (ICRS)

Thu, 22 Jun 2017 05:30:00 EDT

Report on Impact of NB1111 on Tissues that Regulate Intraocular Pressure (IOP) in an Animal Normotensive Ocular Model